Myriad Genetics Inc
Latest Myriad Genetics Inc News and Updates
This Could Be a Solid Growth Driver for Myriad Genetics in 2018
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018
Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).
Myriad Genetics Up after UnitedHealth’s Favorable Decision
Yesterday, Myriad Genetics submitted an 8K filing with the SEC announcing a favorable coverage decision by UnitedHealth Group.
Myriad Genetics Saw Positive Results from GeneSight Trial
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.
Reimbursement for Myriad Genetics’ GeneSight in Fiscal 2018
In fiscal 2018, Myriad Genetics (MYGN) expects to witness rapid expansion in reimbursement for GeneSight based on positive results of the 1,200-patient pharmacogenomic study.
Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication
On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).
How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.
Agios Stock Rises on Higher Trading Volumes on June 8
Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.
Pomalyst and Abraxane Revenues Are Critical for Celgene
Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.
Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%
Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.
Halozyme Therapeutics gets huge 60% increase in Iridian holdings
Iridian Asset Management now holds 11,625,215 shares of Halozyme Therapeutics Inc. (HALO), a huge 60% increase. The fund has a 9% stake in the company.
